ATC Group: L04AC07 Tocilizumab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L04AC07 in the ATC hierarchy

Level	Code	Title
`1`	L	Antineoplastic and immunomodulating agents
`2`	L04	Immunosuppressants
`3`	L04A	Immunosuppressants
`4`	L04AC	Interleukin inhibitors
`5`	L04AC07	Tocilizumab

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
PAREN	Parenteral	20 mg

Active ingredients in L04AC07

Active Ingredient
Tocilizumab
Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R). IL-6 is involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, induction of hepatic acute phase protein synthesis and stimulation of haemopoiesis. IL-6 has been implicated in the pathogenesis of diseases including inflammatory diseases, osteoporosis and neoplasia.

Related product monographs

Document	Type	Information Source
ACTEMRA Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
RoACTEMRA Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)
RoACTEMRA Solution for injection in pre-filled syringe	MPI, EU: SmPC	European Medicines Agency (EU)
TYENNE Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)